Last updated on March 2016

A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS


Brief description of study

The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).

Clinical Study Identifier: NCT02633657

Contact Investigators or Research Sites near you

Start Over

Camilla Alexander

Xenoport Investigational Site
Redwood City, CA United States
  Connect »

Camilla Alexander

Xenoport Investigational Site
San Diego, CA United States
  Connect »

Camilla Alexander

Xenoport Investigational Site
Columbia, SC United States
  Connect »

Camilla Alexander

Xenoport Investigational Site
Nashville, TN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.